active clinically significant bleeding

This is clinically relevant today.

Neither of these findings is of clinical relevance.

No clinically significant effect on efavirenz pharmacokinetics.

The degree of reduction is likely to be clinically significant (see section 4.5).

Digoxin prasugrel has no clinically significant effect on the pharmacokinetics of digoxin.

No clinically relevant effects on Cmax or AUC were observed.

There is no clinically important effect on serum uric acid or urinary uric acid secretion.

Gender had no clinically meaningful effect on the pharmacokinetics of laropiprant.

Age had no clinically meaningful effect on the pharmacokinetics of laropiprant.

Ambrisentan did not have any clinically relevant effects on the pharmacokinetics of tadalafil.

A very small statistically significant but clinically irrelevant effect was found.

However, the pericardial effusion was clinically significant in 2 patients with some associated haemodynamic compromise.

This effect of age is not clinically significant and does not warrant a dose adjustment.

Population pharmacokinetic analysis indicated that oral antidiabetics, diuretics, insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on pregabalin clearance.

Age alone had no clinically relevant effect on pharmacokinetic parameters.

Warfarin also had no clinically significant effects on the pharmacokinetics of ambrisentan.

Repaglinide is almost completely metabolised, and no metabolites with clinically relevant hypoglycaemic effect have been identified.

Age alone had no clinically relevant effect on pharmacokinetic parameters.

Food may increase the amount of loratadine absorbed, but without clinically significant results.

The time of dosing (morning versus evening) had no clinically relevant effects on the rate and extent of absorption.

However, administration of pregabalin with food has no clinically significant effect on the extent of pregabalin absorption.

The clinical effect of the decreased exposure has not been formally assessed but it is likely to be clinically significant.

Ambrisentan did not have any clinically relevant effects on the pharmacokinetics or pharmacodynamics of warfarin.

Gender had no clinically relevant effect on pharmacokinetic parameters.

There was no clinically significant effect of lamotrigine on QT interval compared to placebo.

The effect of other co administered chemotherapies on Avastin clearance is considered not clinically significant.

BYETTA is not expected to have any clinically relevant effects on the pharmacokinetics of metformin or sulphonylureas.

BYETTA is not expected to have any clinically relevant effects on the pharmacokinetics of metformin or sulphonylureas.

No clinically relevant effects on heart rate and blood pressure have been observed in clinical trials.

Gender has no clinically meaningful effect on pharmacokinetics of nicotinic acid (prolonged release formulation).

Gender had no clinically relevant effect on pharmacokinetic parameters.

Gender had no clinically relevant effect on pharmacokinetic parameters.

Limited data suggest there is no clinically significant effect on valproic acid pharmacokinetics.

inhibitors appear to have no clinically relevant effect on zonisamide pharmacokinetic exposure parameters.

Food, including a high fat diet, has no clinically significant effect on gabapentin pharmacokinetics.

In patients with clinically significant third space fluid, consideration should be given to draining the effusion prior to pemetrexed administration.

Ranitidine administration together with Pradaxa had no clinically relevant effect on the extent of absorption of dabigatran.

The clinical effect of the decreased exposure has not been formally assessed but it is likely to be clinically significant.

The effect is maintained for a few days, thereafter slowly declines and is clinically insignificant by two weeks after end of EMEND treatment.

In vivo, nateglinide has no clinically relevant effect on the pharmacokinetics of medicinal products metabolised by CYP2C9 and CYP3A4.

Despite the marked decrease in blood pressure, Losartan had no clinically significant effects on heart rate.

Products metabolised by cytochrome P450

RISPERDAL does not show a clinically relevant effect on the pharmacokinetics of lithium, valproate, digoxin or topiramate.

The effect is maintained for a few days, thereafter slowly declines and is clinically insignificant by two weeks after end of oral aprepitant treatment.